DNMT3A and acute myeloid leukemia: This study provides key insightsinto the pharmacophores of compound 1a for DNMT3A, whichitself is significantly improved overcurrently used drugs to treat AML.20 Bysynthesizing a set of 13 derivative compounds, we showed that thetetrazole and phthalazinone moieties are critical for inhibitory activity.Moreover, the elimination of a lipophilic R4 moiety ledto a decrease in potency.